I personally think it was a big mistake not to buy

New Post Public Reply Private Reply Replies (3) Message Board
aidenb reallypeople? #46623
942
I personally think it was a big mistake not to buy IncellDx. Dr. Patterson is a good scientist and good at developing new products(kits). He would have made us billions of dollars for hist tests. (paid for the BO itself)

Now, Bruce has used CytoDyn data to understand the issue and create kits, and once Bruce's kit are approved, as opposed to selling them, they have get a mediator or go for a trial on why the he built a kit with the data, for which he was paid for his consultation.

At the end we are going to own some of his sales, but at a costs of months or year of mediation or fight.

Even now, it is easier to buy his company, and work out for a number of years, for a cost, and sure he can make us get to the market faster, get new indications, and supplementary kits.

Again, I'm not the BOD of CytoDyn, but I hope someone read this, and think it might be a win-win for both corps.

Quote:
Interesting poster on SA


OU2G
Comments188 | + Follow
Dr. Patterson nails it again and has put fear into those shorting this company. I have no doubt the share price will be going up on Monday because he infused confidence into the blackhole of certainty Nader creates.
It is time CYDY admit that Bruce is a ringer for representing the Covid 19 indications for Leronlimab. Bruce CREATED the science and IS the best most credible spokesperson for CYDY on CV19 and Cancer - period. Dr. Jay is nice, Dr. Yang is helpful however Dr. Patterson is the most important to shareholders... not just for PR.
Ask yourself, where would the share price be if Bruce was welcomed to collaborate with CYDY vs. being pushed away by Nader and Kelly. Could we have held around $8, 20% off the high pre June 30th short attack during these volatile OTC days?
Why didn’t CYDY strike a revenue sharing deal with Bruce? Based on what I heard last night, Incelldx’s test kits are going to make a killing and CYDY investors will be forced to watch from the sidelines or does Nader and Co. have something more obtuse in mind? Like, challenge his patent... whoa.
Which choice will Nader and Co. make?
1) Ignore Bruce and give up diagnostics revenue
2) Challenge patent and directly compete
3) Partner
4) Merge/acquire
Isn’t it funny how junior executives can’t see two moves ahead? I would like them to explain to investors why they don’t see diagnostics for this platform drug as important if they chose option 1, the apparent course we are on.
If they make choice 2 and challenge his patent, I’m definitely selling. Bruce mentioned several “other MABs that are very exciting” so that means we could lose Bruce to the next smart pharmaceutical that would treat him right. I invested in Bruce, and many of you did too, so if that is the plan, we all have to consider the implications.
Regardless, it is clear, Bruce will gladly switch teams if he finds a drug that is better for humanity and that is a complement to Bruce and a direct result of Nader and Co. Not choosing options 3 or 4.
Furthermore, remember that comment Nader said about “we don’t need research” well, that is another astonishing statement made by our illustrious CEO that illustrates the shortsightedness of this executive team.
I wonder if the increased market cap that Bruce might bring be worth avoiding the “lose or lose more” scenarios presented in options 1 and 2 that Nader and Co seem hellbent to make.
I do.
Let’s hope Nader’s stubborn leadership style doesn’t end in the mantra
“Fire Nader. Save CytoDyn.”
From one former CEO to another - stop self-inflicting injury.
OU (edited)

Read More: https://investorshangout.com/post/newpost/605...z6TvED9mnQ
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Group 1 Automotive Q3 2026: Profits Soar, Revenues Dip

Updated Category News Views 19

Profits Up, Revenues Down Here's a tale for the books—Group 1 Automotive reports their third quarter results of 2026 and it's a bit like swapping a thunderstorm for a hurricane. Net income from continuing operations stomped on last year's figures, clocking in at a hefty $102.9 million compared to a skimpy $13.1 million. But don't let that fool you, their total revenues...

Continue Reading
MidCap Financial Faces Scrutiny Amid Ares Capital Merger

Updated Category News Views 62

MidCap Financial's Merger Sparks Legal Action Nobody expects their investments to end up in a courtroom drama, but here we are. MidCap Financial Investment Corporation (NASDAQ: MFIC) is under the microscope, thanks to attorney Juan Monteverde's M&A Class Action Firm. From their perch in the Empire State Building, Monteverde & Associates, celebrated as a top dog in the ISS...

Continue Reading
Endava Faces Class Action: Investors Eye Their Next Move

Updated Category News Views 87

A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...

Continue Reading
Tabañero Spices Up Holidays with $10 Gift Sets

Updated Category News Views 47

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...

Continue Reading
Heritage Wines Meet Non-Alcoholic Trend: New Deal

Updated Category News Views 25

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...

Continue Reading
Webull Faces Class Action: Deadline Looms Dec 2026

Updated Category News Views 60

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Continue Reading
Valmet's Strategic Moves and Financial Gains Explained

Updated Category News Views 62

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

Continue Reading
Veterinary Implants Market to Hit $0.98B by 2031

Updated Category News Views 7

Veterinary Implants Market: A Growth Tale Something's stirring in the veterinary world, my friend. The Veterinary Implants Devices Market is hitting some serious strides, and we're looking at a valuation touching nearly $0.98 billion by 2031. If you're eyeing the veterinary sector, it's time to sharpen those pencils and take notes on where the trend winds are blowing....

Continue Reading
Brinker International Posts Solid Q1 2027 Earnings

Updated Category News Views 38

Strong Earnings Highlight a Winning Streak Brinker International, folks, has done it again. With the latest release of their first quarter fiscal 2027 results, it’s clear they’ve been hitting the right notes, especially at Chili’s. The numbers don't lie—trust me, I've seen my fair share of earnings calls, and this one's got meat on the bones. Let’s break it...

Continue Reading
Tribal Tech Triumph: ILINX Boosts Proposal Efficiency

Updated Category News Views 72

A New Era for Tribal Operations Well, here's a headline that might've slipped under your radar, but it’s got some serious implications. Over in Olympia, Washington, ImageSource, Inc., the brains behind the ILINX platform, just scored a home run with an automated system for crafting Tribal Indirect Cost Rate Proposals (ICRPs). This ain't just gadget talk; this is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Heineken's €1.5 Billion Share Buyback Program: Details Inside

Updated Category News Views 267

Heineken N.V. Updates on Share Buyback Program Heineken N.V., known for its international reach and premium beer brands, has made significant strides in its share buyback program aimed at enhancing shareholder value. The company announced key transaction details related to its substantial €1.5 billion share buyback initiative. Overview of Recent Transactions Commencing...

Continue Reading
TME Pharma Engages in Strategic Partnership for Growth

Updated Category News Views 139

TME Pharma Sets New Horizons with Strategic Investment TME Pharma N.V. (Euronext Growth Paris: ALTME), a pioneering clinical-stage biotechnology company that focuses on innovative solutions for cancer and eye diseases, is taking significant steps to broaden its investment strategy. This shift aims at diversifying its holdings through collaborative endeavors, notably with...

Continue Reading
A.I.S. Resources Gears Up for Gold Exploration and Growth

Updated Category News Views 119

A.I.S. Resources Prepares for Gold Exploration and Growth A.I.S. Resources Limited (TSX-V: AIS, OTC: AISSF) has made exciting announcements regarding its gold exploration activities in Australia. With the gold market showing positive trends, the company is strategically positioning itself to seize the opportunities on the horizon. This renewed emphasis on exploration...

Continue Reading
Micro Flute Paper Market Flourishes Amid Eco-Friendly Trends

Updated Category News Views 341

Micro Flute Paper Market Growth Drivers The global micro flute paper market is experiencing remarkable growth, with forecasts indicating an increase from USD 2,175.2 million in 2025 to an impressive USD 3,443.2 million by 2035. This growth trajectory, representing a compound annual growth rate (CAGR) of 4.7%, reflects the shift towards sustainable packaging solutions. The...

Continue Reading
ProBio Showcases Cutting-Edge Innovations at ASGCT 2025

Updated Category News Views 185

ProBio Showcases Cutting-Edge Innovations at ASGCT 2025 ProBio recently announced its participation in the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, where it will feature six informative poster presentations that delve into the latest advancements in the realm of DNA and viral vector manufacturing. These presentations underscore ProBio's...

Continue Reading